They are prepared by compounding pharmacies under a valid prescription
Typical Allulose Doses and GLP-1 Activation Thresholds Clinical studies show that GLP-1 activation becomes measurable at approximately 5 grams of allulose, with peak response typically observed between 10 and 25 grams per serving
For comparison, semaglutide tops out around 15% and tirzepatide around 21%
The evidence reviewed on this page does not support claims of efficacy for any human disease or condition
Orforglipron Orforglipron , sold under the brand name Foundayo , is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company
"The Efficacy of Third-Party Testing in Authenticating Dietary Supplements: A Case Study on Glutathione." International Journal of Food Safety and Quality Assurance, 18(2), 112-128